Search results for "Gonadotropin"

showing 10 items of 113 documents

Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.

2021

Objective To compare ovarian response and reproductive outcomes in oocyte donors undergoing pituitary suppression with medroxyprogesterone acetate (MPA) versus those undergoing conventional treatment with a gonadotropin-releasing hormone (GnRH) antagonist. Design A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes. The reproductive outcomes of the recipients were retrospectively analyzed later. Setting A university-affiliated private in vitro fertilization center. Patient(s) We randomly divided 318 donors into 2 groups in a 1:1 ratio. The oocytes obtained were assigned to 364 recipi…

0301 basic medicineAdultmedicine.drug_classmedia_common.quotation_subjectMedroxyprogesterone AcetateGonadotropin-releasing hormone antagonistAndrologyGonadotropin-Releasing Hormone03 medical and health sciences0302 clinical medicineOvulation InductionPregnancyFollicular phasemedicineMedroxyprogesterone acetateHumansProspective StudiesGanirelixOvulationmedia_common030219 obstetrics & reproductive medicineEstradiolOocyte Donationbusiness.industryAntagonistObstetrics and GynecologyLuteinizing HormoneMiddle AgedFollicular fluid030104 developmental biologyReproductive MedicineFemaleLuteinizing hormonebusinessmedicine.drugFertility and sterility
researchProduct

Apolipoprotein B is regulated by gonadotropins and constitutes a predictive biomarker of IVF outcomes

2016

Background Follicular fluid (FF) is an important micro-environment influencing oocyte growth, its development competence, and embryo viability. The FF content analysis allows to identify new relevant biomarkers, which could be predictive of in vitro fertilization (IVF) outcomes. Inside ovarian follicle, the amount of FF components from granulosa cells (GC) secretion, could be regulated by gonadotropins, which play a major role in follicle development. Methods This prospective study included 61 female undergoing IVF or Intra-cytoplasmic sperm injection (ICSI) procedure. Apolipoprotein B (APOB) concentrations in follicular fluid and APOB gene and protein expression in granulosa cells from rep…

0301 basic medicineApolipoprotein Bmedicine.medical_treatment[SDV]Life Sciences [q-bio]Human follicular fluidOocyte RetrievalChorionic GonadotropinHuman chorionic gonadotropinFollicle-stimulating hormone0302 clinical medicineEndocrinologyProspective Studies030219 obstetrics & reproductive medicinebiologyObstetrics and Gynecology[SDV] Life Sciences [q-bio]Treatment Outcomemedicine.anatomical_structureFemalelipids (amino acids peptides and proteins)Apolipoprotein BEmbryo qualityAdultmedicine.medical_specialtyendocrine systemEmbryonic DevelopmentFertilization in Vitro03 medical and health sciencesOvulation InductionInternal medicinemedicineIVF outcomesHumansOvarian follicleApolipoproteins BHuman granulosa cellsGranulosa CellsIn vitro fertilisation[ SDV ] Life Sciences [q-bio]ResearchEmbryo MammalianOocyteFollicular fluidFollicular Fluid030104 developmental biologyEndocrinologyReproductive MedicineFertilizationbiology.proteinFollicle Stimulating HormoneBiomarkersGonadotropinsDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Gene Expression and Apoptosis Levels in Cumulus Cells of Patients with Polymorphisms of FSHR and LHB Undergoing in Vitro Fertilization Program

2017

Background/Aims: FSH receptor (FSHR) Ala307Thr and Asn680Ser and LHβ chain (LHB) Trp28Arg and Ile35Thr polymorphisms affect the response to pharmacological ovarian stimulation with r-FSH in women undergoing assisted reproductive treatment (ART). Here, we evaluated the expression level of selected genes involved in follicle maturation and the possible onset of apoptosis in cumulus cells of patients with single and double FSHR and LHB polymorphisms, as potential markers of oocyte competence. Methods: Cumulus cells from 36 stimulated patients were collected and SNP genotyping performed by PCR. Gene expression was evaluated through real-time PCR, and apoptosis estimated via TUNEL assay, and cle…

0301 basic medicineApoptosis; Cumulus cells; FSHR; Gene expression; LH; Polymorphism; PhysiologyLHPhysiologyApoptosislcsh:PhysiologyGonadotropin-Releasing Hormone0302 clinical medicineGene FrequencyFSHRGene expressionlcsh:QD415-436Settore BIO/06 - Anatomia Comparata E CitologiaCells CulturedIn Situ Hybridization Fluorescence030219 obstetrics & reproductive medicinelcsh:QP1-981Caspase 3Apoptosis; Cumulus cells; FSHR; Gene expression; LH; Polymorphismmedicine.anatomical_structureCumulus cellReceptors FSHDNA fragmentationFemaleSignal TransductionAdultHeterozygotemedicine.medical_specialtyendocrine systemGenotypeGranulosa cellCumulus cellsDNA FragmentationFertilization in VitroBiologyReal-Time Polymerase Chain ReactionBuserelinPolymorphism Single Nucleotidelcsh:Biochemistry03 medical and health sciencesFollicleInternal medicinemedicineHumansPolymorphismApoptosiHeterozygote advantageLuteinizing Hormone beta SubunitOocyte030104 developmental biologyEndocrinologyHaplotypesApoptosisMultivariate AnalysisOocytesGene expressionFollicle-stimulating hormone receptorProto-Oncogene Proteins c-aktCellular Physiology and Biochemistry
researchProduct

Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and…

2017

Incidence and prevalence of inflammatory liver diseases has increased over the last years, but therapeutic options are limited. Pregnancy induces a state of immune tolerance, which can result in spontaneous improvement of clinical symptoms of certain autoimmune diseases including autoimmune hepatitis (AIH). We investigated the immune-suppressive mechanisms of the human pregnancy hormone, chorionic gonadotropin (hCG), in the liver. hCG signaling activates silent mating type information regulation 2 homolog 1 (SIRT1), which deacetylates forkhead box o3 (FOXO3a), leading to repression of proapoptotic gene expression, because the immunosuppressive consequence attributed to the absence of caspas…

0301 basic medicineCD4-Positive T-Lymphocytesmedicine.medical_specialtymedicine.drug_classInflammationAutoimmune hepatitisChorionic GonadotropinSensitivity and SpecificityHuman chorionic gonadotropinImmune tolerance03 medical and health sciencesMiceRandom Allocation0302 clinical medicineImmune systemSirtuin 1Internal medicinemedicineJournal ArticleAnimalsHumansComparative StudyCells CulturedMice Inbred BALB CHepatologybusiness.industryCaspase 3Forkhead Box Protein O3Hepatologymedicine.diseaseDisease Models AnimalHepatitis Autoimmune030104 developmental biologyEndocrinology030220 oncology & carcinogenesisImmunologyHepatocytesFemaleGonadotropinmedicine.symptombusinessHormoneSignal TransductionHepatology
researchProduct

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

Does the level of serum antimüllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?

2012

Abstract OBJECTIVE: To determine possible prediction of regular menses with aging in anovulatory women with polycystic ovary syndrome (PCOS). DESIGN: Cohort. SETTING: Academic practice. PATIENT(S): A total of 54 anovulatory women with PCOS and 28 age- and weight-matched control subjects. INTERVENTION(S): Blood and ovarian ultrasound at baseline and after 5 years. MAJOR OUTCOME MEASURE(S): Serum antimüllerian hormone (AMH), gonadotropins, androgens, insulin sensitivity, and ovarian ultrasound. RESULT(S): After 5 years, there was a significant decrease in AMH in women with PCOS and control subjects (10 of 54 anovulatory women became ovulatory after 5 years). There was a significant negative c…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyAgingSettore MED/09 - Medicina Internaendocrine system diseasesmedia_common.quotation_subjectSettore MED/13 - EndocrinologiaBody Mass IndexCohort StudiesPCOS AMH Fertility Ovarian function Ovulation Aging HyperandrogenismPredictive Value of TestsInternal medicinemedicineHumansProspective StudiesProspective cohort studyOvulationmedia_commonUltrasonographyAntimullerian Hormonebusiness.industryOvaryObstetrics and GynecologyMiddle AgedPolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEndocrinologyReproductive MedicinePredictive value of testsCohortAndrogensFemaleInsulin ResistancebusinessBody mass indexBiomarkersGonadotropinsCohort studyAnovulationPolycystic Ovary SyndromeFertility and sterility
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical & Gynecological Survey
researchProduct

The endocrine pattern of late onset adrenal hyperplasia (21-hydroxylase deficiency)

1984

We describe 5 adult women with severe hirsutism due to late onset 21-hydroxylase deficiency. Diagnosis was performed on the finding of high serum 17-hydroxyprogesterone (17OHP) levels with a marked hyperresponse to an ACTH test. The endocrine study showed in most patients a gonadotropin behavior similar to that observed in classical polycystic ovary (PCO) syndrome. Prolactin levels were slightly increased in basal conditions and presented an exaggerated response to TRH stimulation.

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismLate onsetEndocrinologyAdrenocorticotropic HormoneInternal medicineHydroxyprogesteronesmedicineHumansEndocrine systemGonadal Steroid HormoneshirsutismAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneVirilization21-HydroxylaseLuteinizing Hormonemedicine.diseasePolycystic ovaryProlactinProlactinEndocrinologySteroid Hydroxylasesbiology.proteinFemaleSteroid 21-HydroxylaseFollicle Stimulating Hormonemedicine.symptomGonadotropinbusinesshormones hormone substitutes and hormone antagonistsJournal of Endocrinological Investigation
researchProduct

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

2011

Objective: To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists. Design: Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared. Setting: University-affiliated private infertility clinic. Patient(s): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle. Intervention(s): Recombinant LH administration since stimulation day 1. Main Outcome Measure(s): Implantation rate, ongoing pregnancy rate. Result(s): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% …

AdultInfertilitymedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneOvulation InductionPregnancymedicineGnRH antagonistHumansEmbryo ImplantationSperm Injections IntracytoplasmicGynecologyPregnancyIn vitro fertilisationbusiness.industryObstetrics and GynecologyOdds ratioLuteinizing Hormonemedicine.diseaseRecombinant ProteinsConfidence intervalPregnancy rateReproductive Medicineluteinizing hormoneDrug Therapy CombinationFemaleOvarian stimulationFollicle Stimulating HormoneLuteinizing hormonebusinessInfertility Femalein vitro fertilizationMaternal Age
researchProduct

Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradi…

1999

A total of 30 young infertile patients who exhibited a poor response in two previous consecutive cycles, despite having normal basal follicle stimulating hormone (FSH) and oestradiol concentrations, were invited to participate in a prospective randomized study comparing the clinical efficacy of recombinant (rFSH) and urinary (uFSH) follicle stimulating hormone. An evaluation of the total dose used (3800 IU versus 4600 IU, P < 0.05) and duration of treatment (10.2 days versus 13.2 days, P < 0.05) showed a significantly shorter treatment period as well as a significantly lower total dose of FSH required to induce ovulation successfully in the group of patients treated with rFSH. Significantly…

AdultInfertilitymedicine.medical_specialtymedicine.drug_classUrinary systemmedia_common.quotation_subjectBiologyBasal (phylogenetics)Follicle-stimulating hormoneOvulation InductionPregnancyInternal medicinemedicineHumansEmbryo ImplantationProspective StudiesOvulationmedia_commonPregnancyEstradiolRehabilitationPregnancy OutcomeObstetrics and Gynecologymedicine.diseaseRecombinant ProteinsEndocrinologyReproductive MedicineEstrogenFemaleFollicle Stimulating HormoneGonadotropinHuman Reproduction
researchProduct